Akebia Therapeutics Inc. (AKBA)
NASDAQ: AKBA
· Real-Time Price · USD
3.19
-0.06 (-1.85%)
At close: Aug 18, 2025, 10:38 AM
Akebia Therapeutics Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | -45.31M | -69.41M | -45.99M | -40.44M | -43.69M | -51.93M | -60.09M | -97.47M | -56.36M | -92.56M | -155.69M | -163.37M | -275.68M | -282.84M | -299.16M | -299.58M | -392.29M |
Depreciation & Amortization | 28.44M | 37.5M | 37.56M | 37.6M | 37.59M | 37.63M | 37.64M | 37.66M | 37.68M | 37.7M | 37.73M | 37.79M | 37.87M | 37.97M | 36.24M | 33.38M | 33.49M |
Stock-Based Compensation | 7.6M | 7.78M | 7.59M | 7.77M | 9.19M | 9.32M | 10.84M | 12.38M | 15.8M | 17.85M | 19.44M | 21.68M | 21.28M | 22.73M | 24.19M | 25.19M | 25.54M |
Other Working Capital | 21.39M | 180K | 2M | -12.37M | -6.25M | -13.94M | -46.84M | -43.64M | -105.58M | -34.42M | -55.18M | -37.85M | 4.62M | -46.81M | -1.35M | -51.45M | -38.49M |
Other Non-Cash Items | 24.45M | 39.27M | 75.4M | 101.45M | 67.35M | 45.63M | -56.7M | -35.1M | -39.65M | -34.7M | 40.81M | 15.57M | 53.64M | 41.01M | 35.88M | 39.17M | 17.75M |
Deferred Income Tax | n/a | n/a | -44.3M | -43.58M | -43.3M | -43.3M | 992K | 277K | n/a | n/a | 8.38M | 10.08M | 9.86M | 36.58M | 58.31M | 73.6M | 219.39M |
Change in Working Capital | -17.81M | -3.23M | -16.21M | -49.2M | -32.04M | -20.73M | -8.44M | 47.47M | -26.54M | -1.44M | -31.96M | -93.11M | -50.81M | -108.42M | -76.39M | -63.67M | 4.58M |
Operating Cash Flow | -34.81M | -40.66M | -38.5M | -38.97M | -25.28M | -23.38M | -75.75M | -34.78M | -69.07M | -73.15M | -81.28M | -171.36M | -203.84M | -252.97M | -220.94M | -191.91M | -91.55M |
Capital Expenditures | -20K | -2K | n/a | -29K | n/a | n/a | n/a | n/a | n/a | -114K | -114K | -114K | -114K | -59K | -376K | -421K | -466K |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -49.95M | -99.93M | -99.93M |
Sales Maturities Of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 20M | 40M | 100M | 100M | 80M |
Other Investing Acitivies | 112K | -60K | -60K | -29K | n/a | n/a | n/a | n/a | n/a | -114K | -114K | -114K | 19.89M | 40M | 89.95M | 90.04M | 20.09M |
Investing Cash Flow | 121K | -33K | -31K | -29K | n/a | n/a | n/a | n/a | n/a | -114K | -114K | -114K | 19.89M | 39.94M | 99.62M | 49.69M | -20.31M |
Debt Repayment | 17.16M | 7.9M | -100K | -100K | -15.73M | -32M | -24M | -57M | -49M | -33M | -33M | n/a | n/a | n/a | 19.98M | 19.98M | 19.98M |
Common Stock Repurchased | -63K | -750K | -750K | -750K | -750K | n/a | n/a | n/a | -9K | -9K | -9K | -9K | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | 726K | 385K | 5.59M | 6.12M | 6.85M | 6.71M | n/a | n/a | 67K | 40.07M | 40.07M | 40.07M | 40M | 74.48M | 85.01M | 85.42M | 85.83M |
Financial Cash Flow | 106.13M | 49.66M | 26.05M | 24.88M | 9.23M | -25.21M | -23.92M | -56.9M | -48.91M | 14.6M | 20M | 69.42M | 106.8M | 133.73M | 158.84M | 143.41M | 248.85M |
Net Cash Flow | 73.1M | 10.63M | -10.84M | -14.15M | -16.06M | -48.6M | -99.67M | -91.69M | -117.98M | -58.67M | -61.4M | -102.05M | -77.15M | -79.29M | 37.52M | 1.19M | 137M |
Free Cash Flow | -34.83M | -40.66M | -38.5M | -39M | -25.28M | -23.38M | -75.75M | -34.78M | -69.07M | -73.27M | -81.4M | -171.47M | -203.95M | -253.02M | -221.31M | -192.33M | -92.01M |